Comparison between ATS/ERS age- and gender-adjusted criteria and GOLD criteria for the detection of irreversible airway obstruction in chronic heart failure

Clinical Research in Cardiology

Volumn 101, Issue 8, 2012, Pages 637-645

  Steinacher, Richard ^a   Parissis, John T ^b   Strohmer, Bernhard ^a   Eichinger, Jörg ^a   Rottlaender, Dennis ^a   Hoppe, Uta C ^a   Altenberger, Johann ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Airway obstruction; Chronic obstructive pulmonary disease; Diagnosis; Heart failure; Spirometry

Indexed keywords

ADULT; AGED; AIRWAY OBSTRUCTION; AMERICAN THORACIC SOCIETY CRITERIA; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; EUROPEAN RESPIRATORY SOCIETY CRITERIA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE CRITERIA; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PREVALENCE; SENSITIVITY AND SPECIFICITY; SPIROMETRY;

AGE DISTRIBUTION; AGED; AUSTRIA; COMORBIDITY; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION; SPIROMETRY;

EID: 84865755941     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-012-0438-0     Document Type: Article

References (36)

1. Staszewsky L, Wong M, Masson S, Barlera S, Carretta E, Maggioni A, Anand I, Cohn J, Tognoni G, Latini R (2007) Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: Data from the Val-HeFT heart failure trial. J Card Fail 13:797-804
2. Rusinaru D, Saaidi I, Godard S, Mahjoub H, Battle C, Tribouilloy C (2008) Impact of chronic obstructive pulmonary disease on long-term outcome of patients hospitalized for heart failure. Am J Cardiol 101:353-358
3. Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW (2006) Heart failure and chronic obstructive pulmonary disease: An ignored combination? Eur J Heart Fail 8:706-711
4. Rabe K, Hurd S, Anzueto A, Barnes P, Buist S, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176:532-555
5. Pellegrino R, Viegi G, Brusasco V, Crapo R, Burgos F, Casaburi R, Coates A, van der Grinten C, Gustafsson P, Hankinson J, Jensen R, Johnson D, MacIntyre N, McKay R, Miller M, Navajas D, Pedersen O, Wanger J (2005) Interpretative strategies for lung function tests. Eur Respir J 26:948-968
6. Hankinson J, Odencrantz J, Fedan K (1999) Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 159:179-187
7. Hansen J, Sun X, Wasserman K (2007) Spirometric criteria for airway obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not\70%. Chest 131:349-355
8. Celli B, Halbert R, Isonaka S, Schau B (2003) Population impact of different definitions of airway obstruction. Eur Respir J 22:268-273
9. Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Mørkve O (2002) Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 20:1117-1122
10. Iversen KK, Kjaergaard J, Akkan D, Kober L, Torp-Pedersen C, Hassager C, Vestbo J, Kjoller E, EC-LFS Group (2008) Chronic obstructive pulmonary disease in patients admitted with heart failure. J Intern Med 264:361-369
11. Mascarenhas J, Lourenco P, Lopes R, Azevedo A, Bettencourt P (2008) Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J 155:521-525
12. Tzani P, Piepoli MF, Longo F, Aiello M, Serra W, Maurizio AR, Olivieri D, Chetta A (2010) Resting lung function in the assessment of the exercise capacity in patients with chronic heart failure. Am J Med Sci 339:210-215
13. Cazzola M, Imperatore F, Salzillo A, Di Perna F, Calderaro F, Imperatore A, Matera M (1998) Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 114:411-415
14. Au D, Udris E, Fan V, Curtis J, McDonell M, Fihn S (2003) Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 123:1964-1969
15. Singh S, Loke Y, Furberg C (2008) Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. JAMA 300:1439-1450
16. Bellotti P, Badano L, Acquarone N, Griffo R, Lo Pinto G, Maggioni A, Mattiauda C, Menardo G, Mombelloni P (2001) Specialty-related differences in the epidemiology, clinical profile, management and outcome of patients hospitalized for heart failure; the OSCUR study. Oucome dello Scompenso Cardiaco in relazione all'Utilizzo delle Risore. Eur Heart J 22:596-604
17. George R, Light R, Hudson L, Conrad S, Chetty K, Manocha K, Burford J (1985) Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with asthma and propranolol sensitivity. Chest 88:815-818
18. Salpeter S, Ormiston T, Salpeter E (2005) Cardioselective betablockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (4):CD003566
19. Salpeter S (2009) Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?: A synthesis of the available evidence. Drugs 69:2025-2033
20. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth O, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Le'vy S, Linde C, Lopez-Sendon J, Nieminen M, Pie'rard L, Remme W (2005) Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26:1115-1140
21. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbe'ly A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL (2007) How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28:2539-2550
22. Miller M, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten C, Gustafsson P, Jensen R, Johnson D, MacIntyre N, McKay R, Navajas D, Pedersen O, Pellegrino R, Viegi G, Wanger J (2005) Standardisation of spirometry. Eur Respir J 26:319-338
23. Fabbri L, Pauwels R, Hurd S (2004) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary updated 2003. COPD 1:105-141 (discussion 103-104)
24. Lakatos E (1986) Sample size determination in clinical trials with time-dependent rates of losses and noncompliance. Control Clin Trials 7:189-199
25. Pezzoli L, Giardini G, Consonni S, Dallera I, Bilotta C, Ferrario G, Cristina Sandrini M, Annoni G, Vergani C (2003) Quality of spirometric performance in older people. Age Ageing 32:43-46
26. Faggiano P (1994) Abnormalities of pulmonary function in congestive heart failure. Int J Cardiol 44:1-8
27. Dimopoulou I, Daganou M, Tsintzas OK, Tzelepis GE (1998) Effects of severity of long-standing congestive heart failure on pulmonary function. Respir Med 92:1321-1325
28. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar J, Cohen-Solal A, Dietz R, Gavazzi A, Van Gilst W, Hobbs R, Korewicki J, Madeira H, Moiseyev V, Preda I, Widimsky J, Freemantle N, Eastaugh J, Mason J (2003) The EuroHeart Failure Survey programme -a survey on the quality of care among patients with heart failure in Europe. Part 2: Treatment. Eur Heart J 24:464-474
29. Light R, George R (1983) Serial pulmonary function in patients with acute heart failure. Arch Intern Med 143:429-433
30. Hoke RS, Muller-Werdan U, Lautenschlager C, Werdan K, Ebelt H (2012) Heart rate as an independent risk factor in patients with multiple organ dysfunction: A prospective, observational study. Clin Res Cardiol 101:139-147
31. Reil JC, Custodis F, Swedberg K, Komajda M, Borer JS, Ford I, Tavazzi L, Laufs U, Bohm M (2011) Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol 100:11-19
32. Hoppe UC, La Rosee K, Larbig R, Erdmann E (2007) Selective inhibition of the pacemaker channel I(f) improves symptoms in severe dilated cardiomyopathy. Clin Res Cardiol 96:243-246
33. Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E (2005) Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM 98:493-497
34. George R, Manocha K, Burford J, Conrad S, Kinasewitz G (1983) Effects of labetalol in hypertensive patients with chronic obstructive pulmonary disease. Chest 83:457-460
35. Damarla M, Celli BR, Mullerova HX, Pinto-Plata VM (2006) Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. Respir Care 51:1120-1124
36. Iversen KK, Kjaergaard J, Akkan D, Kober L, Torp-Pedersen C, Hassager C, Vestbo J, Kjoller E, Group ELFS (2010) The prognostic importance of lung function in patients admitted with heart failure. Eur J Heart Fail 12:685-691